loading page

Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders
  • +3
  • Hennique Knobbe,
  • Elvera Damer,
  • Mireille Edens,
  • Bas Nij Bijvank,
  • Marieke Hemels,
  • Peter Ter Horst
Hennique Knobbe
Isala klinieken
Author Profile
Elvera Damer
Isala klinieken
Author Profile
Mireille Edens
Isala klinieken
Author Profile
Bas Nij Bijvank
Isala klinieken
Author Profile
Marieke Hemels
Isala klinieken
Author Profile
Peter Ter Horst
Isala klinieken

Corresponding Author:[email protected]

Author Profile


Abstract Objective To compare the gestational age of neonates in utero exposed to benzodiazepines (BDZs) with none exposed controls. Secondary objectives were; birth weight, presence of congenital malformations, APGAR score, and the need for > 3 months (prolonged) maternal psychiatric care. Study design A retrospective cohort study of women and neonates from 2013 to 2021 with univariate and multivariable analysis to study the associations between BDZs exposure and gestational age compared to non-exposed women with mental health problems. Results We found that BDZ exposure was associated with a lower gestational age of -3.2 days (95% CI -5.8 , -0.53 days). Women in the exposed group had an increased risk of psychiatric care (adjusted OR 2.511 (95% CI 1.675 – 3.782), p < 0.001). Conclusion We found that in utero BDZ exposure was independently associated with a significantly lower gestational age of the neonates and prolonged psychiatric care of their mothers.
16 Dec 2022Submitted to British Journal of Clinical Pharmacology
21 Dec 2022Submission Checks Completed
21 Dec 2022Assigned to Editor
21 Dec 2022Review(s) Completed, Editorial Evaluation Pending
06 Feb 2023Reviewer(s) Assigned
24 Feb 2023Editorial Decision: Revise Major
21 Apr 20231st Revision Received
21 Apr 2023Submission Checks Completed
21 Apr 2023Assigned to Editor
21 Apr 2023Review(s) Completed, Editorial Evaluation Pending
16 May 2023Editorial Decision: Accept